chrisvoncsefalvay/vaers-outcomes huggingface dataset:
On 11/8/2005 I received the Pneumovax vaccine in my right deltoid. Hours later I had intense right arm pain which kept me from sleeping.  The following day I noticed a large area of redness, warmth and swelling extending from the right shoulder to the elbow, especially on the inner aspect of the right arm. This swelling/redness persists today.  I also have had peristent aching of my shoulder and lower back since the vaccine.
CHIEF COMPLAINT:   Pt states, "I got up too fast out of bed and slid. I had a hard time getting up myself. My son helped me." Denies hitting head or LOC. Denies blood thinners.   HISTORY OF PRESENT ILLNESS:     63-year-old gentleman who was recently diagnosed with B-cell lymphoma involving his sigmoid colon, right ureter, lung presenting for the evaluation of generalized weakness.  Patient reports 1 week of progressively worsening weakness and states tonight he was unable to get out of bed which prompted his evaluation in the ED.  He denies falls or head trauma.  Patient does note that he was recently diagnosed with lymphoma and was seen by his oncologist today where he was started on several medications including an antibiotic for a gluteal skin infection.  He is denying fevers or chills.  He reports abdominal pain.  Denies chest pain or shortness of breath.
2/10/22 pt had a positive COVID test at the medical center and was admitted through 2/14/22; pt had increasing SOB and LE edema when she came in; 86% on RA; placed on O2; admitted; pt had A Fib with RVR, was hyperkalemic and hypotensive; family decided on comfort measures for pt; she was dc'd where she passed away
Intense muscle and joint pain. Wheezing. Extreme Fatigue. Nausea. Vomiting. Headache.
pt collapsed; felt dizzy, passed out, felt constriction in throat, BP elevated, dehydrated on admission; had been on golf course; now suffers from constant thirst & insmonia; discharged from hosp w/undetermined diagnosis;
arm very swollen-down 3" from site-lengthening red 4.5" long; 27MAR still swollen & tender but improving;
Information has been received from a physician concerning a 4 year old male with penicillin and shellfish allergies, and a history of reactive airways disease who on 20-SEP-2007 was vaccinated with a first dose of PROQUAD (Merck upgrade process) (SC), and on 29-JUN-2010 he received the second dose (SC, lot # 666885/0283Z). Concomitant therapy included montelukast sodium (MSD). On 30-JUN-2010 the patient developed swelling at the injection site, right triceps region. On 01-JUL-2010 the patient developed a vesicular rash with a 3-5" radius around the site of injection and smaller rashes scattered about his body. No acute treatment was rendered. The patient made an office visit on 02-JUL-2010 and he had no contact with the physician since then. The outcome was unknown. Follow up information received from a licensed practical nurse concerning a 4 year old male patient with penicillin allergy and 2/6 Systolic Ejection Murmur innocent quality, and no illness at time of vaccination, who on 20-SEP-2007 was vaccinated with a first dose of PROQUAD (Merck upgrade process) ( lot # 666885/0283Z) in the right arm, and on 29-JUN-2010 at 4:00 pm he received the second dose (lot # 666885/0283Z) in the right arm. On 30-JUN-2010, the patient developed large area of swelling vesicular rash especially on red area, pustules did form and drain from vesicular rash. The patient required emergency room/doctor visit. There were no labs or diagnostic tests performed. The patient recovered, date unknown. Additional information is not expected.
cardiac effusion following vaccination; plural effusion following vaccination; This spontaneous case was reported by a consumer and describes the occurrence of PERICARDIAL EFFUSION (cardiac effusion following vaccination) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PERICARDIAL EFFUSION (cardiac effusion following vaccination) (seriousness criterion medically significant) and PLEURAL EFFUSION (plural effusion following vaccination). At the time of the report, PERICARDIAL EFFUSION (cardiac effusion following vaccination) and PLEURAL EFFUSION (plural effusion following vaccination) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were reported.   The patient developed pleural effusion and cardiac effusion about a month after the second dose.  Treatment information was not provided.  Very limited information regarding the events has been provided at this time; Sender's Comments: Very limited information regarding the events has been provided at this time
IRREGULAR AND HEAVY PERIOD!!!.   Vaccine received on last day of menstrual cycle. Two days later started spotting on dayly basis and with clots wich continued until I started on  progesterone on April 8, 2021 (prescribed for 10 days).  Even with the pill, I continue to spot lightly. I am unsure about getting the second dose of the Moderna Covid vaccine on 03/15/2021.  Even with a history of previous fibroid removed around 2014.  My period seem has never behave "non-stop" like this.
Headache; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of HEADACHE (Headache) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concomitant products included SEMAGLUTIDE (WEGOVY) for an unknown indication.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced HEADACHE (Headache). At the time of the report, HEADACHE (Headache) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No treatment medication was provided.
lot of itching; I develop small rash about a size of tennis ball; A spontaneous report was received from a consumer concerning a 86-years-old female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced events i develop small rash about a size of tennis ball, lot of itching.  The patient's medical history was not provided. Concomitant medications reported were High Blood Pressure Medication for drug use for unknown indication.  On 22 Jan 2021, prior to the onset of the events the patient received their first of two planned doses of mRNA-1273 (lot/batch: 029L20A) intramuscularly for prophylaxis of COVID-19 infection.  On 22 Jan 2021, the patient experienced the event(s) i develop small rash about a size of tennis ball. lot of itching.  No treatment information was provided.  Action taken with mRNA-1273 in response to the events were not applicable.  The outcome of event(s), i develop small rash about a size of tennis ball, lot of itching was unknown.
Itchy rash in the whole body, NO anaphylaxis. Pharmacist administer Benadryl Intramuscular ( 50mg)
sore arm; Initial information received on 29-Oct-2021 regarding an unsolicited valid social media non-serious case received from a consumer or non-healthcare professional.  This case involves an patient (unknown demographics) who experienced sore arm (pain in extremity) while receiving vaccine INFLUENZA VACCINE.  The patient's past medical treatment, vaccination, concomitant medication and family history were not provided.   It was unknown if the patient had any medical history, concomitant disease or risk factor.  On 28-Oct-2021, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer lot number not reported via an unknown route at an unknown administration site for prophylactic vaccination.  In Oct-2021 the patient developed a non-serious sore arm (pain in extremity) (unknown latency) following the administration of INFLUENZA VACCINE.  It was unknown if the patient experienced any additional symptoms/events.  It was unknown if there were lab data/results available.  It was not reported if the patient received a corrective treatment for the event (sore arm).  The event outcome was unknown for sore arm.  There will be no information available on the batch number for this case.
Sharp pains in chest and back and neck on left side; Sharp pains in chest and back and neck on left side; Sharp pains in chest and back and neck on left side; Tingling in left hand; very swollen and painful lymph nodes under left arm and in neck, and chest area on left side of body; This is a spontaneous report from a contactable consumer (Patient).   A 62-year-old female patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Lot Number: ER8727), at left arm via an unspecified route of administration on 24Mar2021at 15:00 (at the age of 62-year-old), as SINGLE DOSE for COVID-19 immunization. Patient historical condition included mytral valve prolapse. The patient concomitant medications were not reported. Patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Lot Number: EN6203), at left arm via an unspecified route of administration on 03Mar2021 02:45 PM, as SINGLE DOSE for COVID-19 immunization. Patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Patient did not receive any other medications within 2 weeks of vaccination. Patient not diagnosed COVID 19 prior to vaccination. On 25Mar2021 19:00, the patient had sharp pain in chest and back and neck on left side; tingling in left hand; very swollen and painful lymph nodes under left arm and in neck, and chest area on left side of body. Occurred 28 hours after injection and again 90 hours after injection. Patient not received treatment for the adverse event. Since the vaccination, patient not been tested for COVID-19. At the time of this report event outcome was recovering.  No follow-up attempts are needed. No further information is expected.
Expired dose of Td (tetanus & diphtheria) given. Expired 3/5/22, lot  U6603AA. Notified poison control, advised to repeat dose. Patient notified of vaccine error, agreeable to have dose repeated.
This spontaneous report was received from a medical assistant and refers to a 73 year old patient of unknown gender. No information about the patient's pertinent medical history, concomitant medications, drug reactions or allergies was provided. On 29-JAN-2016, the patient was vaccinated with an improperly stored dose of PNEUMOVAX 23 lot # L012521 and expiration date 01-FEB-2017 (dose and route of administration were not reported). The vaccine underwent temperature excursion of 1 degree Celsius for 158 total cumulative hours, which was detected by a data logger. There was no previous temperature excursion. No adverse effects were reported. This is one of several reports received from the same reporter. Additional information has been requested.
Expired vaccine used; This spontaneous case was reported by a health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) in a 59-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 046C21A) for COVID-19 vaccination.     Concurrent medical conditions included Hyperlipidemia since 07-May-2021 and Hypothyroidism since 07-May-2021. Concomitant products included ROSUVASTATIN from 07-May-2021 to an unknown date for Hyperlipidemia, LEVOTHYROXINE from 07-May-2021 to an unknown date for Hypothyroidism.    On 17-Nov-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 17-Nov-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Expired vaccine used). On 17-Nov-2021, EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No treatment medications are provided.  Patient reported allergic to Humira.   This case was linked to MOD-2021-407640, MOD-2021-407570 (Patient Link).
Information has been received from a registered nurse referring to an unspecified number of patients of unknown age and gender. The patients' concurrent conditions, concomitant medication and medical history were not provided. On unknown dates the patients were vaccinated with unspecified doses of improperly stored VAQTA (dose, route and dose number were not provided) (lot # K026529, expiry date 02-JUN-2017) (lot# L007559, expiry date 01-JUN-2017). No adverse effect was reported. This is one of several reports received from the same source. Additional information has been requested.
Information has been received through the Merck pregnancy registry concerning a 29 year old female with no pertinent medical history or no drug reactions/allergies who on approximately 20-APR-2007 was vaccinated with a first dose of GARDASIL (lot # unknown) injection. On 20-JUN-2007 the patient was vaccinated with a second dose of GARDASIL. There was no concomitant medication used. The consumer reported that she had a positive pregnancy test on 10-AUG-2007 (home pregnancy test and blood test). Her last menstrual period date was 17-JUN-2007, and the estimated due date was 23-MAR-2008. At the time of the report, the patient reported she had not had any reactions. Initial and follow up information has been received from the nurse practitioner who indicated that the patient did not carry the pregnancy to term. She indicated that the patient "had significant problems and miscarried the pregnancy." No other records were available. Upon internal review, the patient's miscarriage was considered to be an other important medical event. Additional information has been requested.
5 minutes after injection I experienced a metallic taste in mouth and slight tightening of throat. I waited 20 minutes in observation and spoke to nurse and PA who assured me I should be fine if I had no history of anaphylactic shock. 20 minutes later I still felt tightness in my throat, metallic taste in mouth, headache, and now slight difficulty swallowing, at which time I used my Albuterol rescue inhaler. Tightening in throat resolved within an hour. Metallic taste and headache is still present +2 hours after injection.
pt recv vax; no T elev; sl redness on leg at inject site; leg very sore that is child won't put weight on it or allow mom to move it; lasted for 24 hrs;
SIRS - systemic inflammatory response - rigors, chills, fever 104 for 8 hours and delirium
Feeling jittery; difficulty sleeping; she was not able to sit down; This is a spontaneous report from a Pfizer sponsored Program COVAX US Support. A contactable consumer reported for a female patient (reporter's daughter). A female patient with unspecified age received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: Solution for injection, batch/lot number: unknown) via unknown route of administration on an unknown date as DOSE 1, SINGLE for COVID-19 immunisation. The patient medical history and concomitant medication was not reported. After the vaccine within half an hour the patient felt jittery, could not sit still and could not sleep. The outcome of the events was unknown.  Information about lot/batch number has been requested.
Shot 1 on Dec-2020, has not had shot #2; This case was reported by a consumer via call center representative and described the occurrence of incomplete course of vaccination in a 78-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (received 1st dose on 02nd December 2020, did not remember if the 1st dose was in right or left arm, but the patient thought it was probably in right arm).   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the incomplete course of vaccination was unknown.  Additional details were provided as follows: The reporter was the patient.  The age at vaccination was not applicable for this report. The patient was unable to locate the lot number for the shot given but did provide contact information for the primary care office where the shot was given.  Till the time of reporting, the patient did not receive 2nd dose of Shingrix, which led to incomplete vaccination schedule. The reporter consented to follow up.
Patient said she felt "unwell" day following vaccine, but that passed the following day. Her symptoms fell within the typical expected side effects post-vaccination. However, Friday 2/26 (9 days after 2nd dose) she said she woke up around midnight with chills, vomiting, and diarrhea. This lasted 5-6 hours and then stopped. She hasn't had any problems since and was encouraged to report this event via. She was advised to contact her doctor is symptoms reappear/persist.
pt w/hx of elevated liver function tests, devel elevation of  unspecified liver enzymes p/vax;
Positive covid-19 test. Headache, sore throat, cough, shortness of breath, chest pain
Patient presented to the emergency department at 2242 after being found by her son with left sided facial weakness and hemiparesis. Last known well was 2030.
About 2 days after 2nd vaccine injection left arm began hurting and has only become worse over time. Arm feels very heavy, extremely sore going up into my neck. Hard to use arm because of pain
Patient fainted in waiting area after receiving immunization. Patient experienced visual disturbances seeing black spots, left sided chest pain, and arm tingling. Checked patient blood pressure, elevated her legs, applied cold ice pack behind her neck. Called 911 and paramedics arrived on time.
My nerves were on fire and still bug me; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of NEURALGIA (My nerves were on fire and still bug me) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced NEURALGIA (My nerves were on fire and still bug me). At the time of the report, NEURALGIA (My nerves were on fire and still bug me) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were reported. No treatment details was reported by the reporter.
Moderna booster was administered 1/19/22 around 530 pm. Body pain and fatigue started approximately 4 hours later. Within the first 24 hours headache, tinnitus, body pain, joint pain, fatigue, weakness and arm pain at injection site.. These symptoms lasted approximately 48-72 hours. HOWEVER, THE TINNITUS HAS CONTINUED ON A DAILY BASIS AND HAS NOT RESOLVED.
Felt "tired"; A little bit of itching; This is a spontaneous report from a contactable consumer (patient). A 32-year-old female patient received received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, Lot number: unknown), via an unspecified route of administration on 06Apr2021 at single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. On an unspecified date the patient stated that after the injection, she felt "tired" and that night she experienced "a little bit of itching". She added the next day, she "was fine" then the itching came back therefore she went to the ER. She specified the doctor prescribed benadryl which she started yesterday. She asked if her symptoms were reported as side effect to the vaccine. The patient asked if she should be concerned about the itchiness she is experiencing and after getting the first dose and in response that reiterated risks of the vaccine, provided antihistamine usage info and encouraged consultation with HCP for further guidance. The outcome of the events was unknown.  No follow-up attempts are needed. No further information is expected.
A non-serious spontaneous report of "we inadvertently gave H1N1 to a person > 49" was received from a registered nurse concerning an adult female. Neither relevant medical history nor concomitant medications were reported. The product expires on 01-Jan-2010. On 09-Nov-2009, the patient received H1N1, Intranasal. There was no adverse event associated with this medication error; therefore, treatment and reporter causality assessments are not applicable, and the event is considered resolved.
p/vax pt devel lt arm redness & swelling in a two to three inch area that was warm & painful to touch;pt also reported feeling blah;pt sx resolved in two days w/only sl redness @ the inj site;nurse reported pt recovered
This is a spontaneous report from a contactable nurse reporting for him/herself via a Pfizer sales representative. A patient of unspecified age, race/ethnicity and gender received PREVNAR 13, via an unspecified route of administration, on an unspecified date, at single dose, for immunisation. Relevant medical history and concomitant medications were not reported. The patient experienced pain when vaccine was injected on an unspecified date with outcome of unknown. No follow-up attempts possible. No further information expected.
Pain, swelling, redness, hard area, and heat to the area where immunization was given.  Cellulitis.
One hour after receiving 2009 H1N1 nasal mist, noticed redness around mouth. Three days later noted raised red rash under the eyes without swelling. Redness around mouth bright red color. Four and half hours later, rash noted of neck, no dyspnea. Call physician, instructed to take Benadryl 50mg. 1/12/10 - Mother states rash a redness completely resolved this A.M.
feels heavy; chest pain; pain on left hand; This spontaneous case was reported by a consumer and describes the occurrence of CHEST PAIN (chest pain), PAIN IN EXTREMITY (pain on left hand) and DISCOMFORT (feels heavy) in a 57-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 025C21A and 025B21) for COVID-19 vaccination.     No Medical History information was reported.   On 07-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 06-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 19-May-2021, the patient experienced CHEST PAIN (chest pain) and PAIN IN EXTREMITY (pain on left hand). On an unknown date, the patient experienced DISCOMFORT (feels heavy). At the time of the report, CHEST PAIN (chest pain) and PAIN IN EXTREMITY (pain on left hand) had not resolved and DISCOMFORT (feels heavy) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, SARS-CoV-2 test: negative (Negative) Negative.         no concomitant medication were reported no treatment medication were reported
Pt. states that after receiving the 1st dose of Moderna 01/06/2021, started experiencing symptoms of fatigue and soreness of the Left arm lasting 4 days. No noted Primary visit/communications.
Case number PHEH2013US015594 is an initial spontaneous report received from a nurse on 18 Jul 2013 with a follow up information received on 24 Jul 2013. This report reefers to an 11-years and 2-months old male patient. His medical history and concomitant medications were not reported. He was vaccinated with MENVEO, (batch number: M11032, expiry date: not available) at a dose of 0.5 ml intramuscularly on 15 Jun 2013. His parent reported on 16 Jun 2013 that on unknown date he experienced itchiness, redness and swelling around the vaccination site. The outcome of the event was not reported. No further information was provided. Follow up information received on 24 Jul 2013: Batch number of the vaccine updated.